UNC startup GeneVentiv Therapeutics is developing the first universal, single-dose gene therapy for all types of hemophilia, including the toughest cases.

Why is UNC-Chapel Hill poised to make a growing impact through innovation and entrepreneurship? Two leaders of Innovate Carolina talk partnerships, team-driven innovation and new ways the University is expanding innovation for all.

UNC-Chapel Hill, Duke University and the North Carolina Biotechnology Center highlight the importance of strengthening a regional ecosystem of scientific and entrepreneurial expertise by helping life science startups gain exposure, build connections, and get feedback from potential investors.

UNC startup Pulvinar Neuro’s novel treatment for mental illness – a technology that uses closed-loop, non-invasive stimulation of brain waves – offers hope to a rising tide of patients and recently led to the company’s acquisition by medical device leader Electromedical Products International.